-
Fresenius Kabi USA, LLC et al v. Sagent Pharmaceuticals, Inc. DC
- 1:17-cv-00011
- D. Del.
- Judge: Leonard P. Stark
- Filed: 01/04/2017
- Closed: 06/09/2017
- Latest Docket Entry: 06/16/2017
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
2
Patents-in-Suit
157
Days in
Litigation
-
Fresenius Kabi USA, LLC et al v. Sagent Pharmaceuticals, Inc. DC
- 1:17-cv-00011
- D. Del.
- Judge: Leonard P. Stark
- Filed: 01/04/2017
- Closed: 06/09/2017
- Latest Docket Entry: 06/16/2017
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Sagent Pharmaceuticals Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| A ropivacaine hydrochloride injection product containing 2 mg ropivacaine hydrochloride per 1 mL formulation, in 100 mL and 200 mL infusion bagsa ropivacaine hydrochloride injection product containing 5 mg ropivacaine hydrochloride per 1 mL formulation, in 100 mL and 200 mL infusion bags | US 8,118,802 B2 | All Asserted Claims |
Infringement
Entry 9
|
| A ropivacaine hydrochloride injection product containing 2 mg ropivacaine hydrochloride per 1 mL formulation, in 100 mL and 200 mL infusion bagsa ropivacaine hydrochloride injection product containing 5 mg ropivacaine hydrochloride per 1 mL formulation, in 100 mL and 200 mL infusion bags | US 8,162,915 B2 | All Asserted Claims |
Infringement
Entry 9
|
